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ABSTRACT
Background Fabry disease (FD) is a rare X- linked 
lysosomal storage disease caused by mutations 
in the α-galactosidase A gene (GLA) leading to 
deficiency of α-galactosidase A and ultimately in 
progressive glycosphingolipid accumulation, especially 
globotriaosylceramide (Gb3) and its deacylated derivative 
globotriaosylsphingosine (Lyso- Gb3). The aim of the 
study was to assess plasma Lyso- Gb3 levels as a possible 
factor associated with adverse outcomes in FD.
Methods In a cohort of 66 patients with genetically 
confirmed FD (26 males and 40 females), we analysed 
serum Lyso- Gb3 as a factor associated with adverse 
clinical outcomes in a long- term study. The main 
outcome was a composite endpoint of incident kidney 
replacement therapy, atrial fibrillation, pacemaker and/
or implantable cardioverter defibrillator, cerebrovascular 
events or death, whichever occurred first.
Results During the median follow- up time of 68 
(40–80) months, events occurred in 19 (29%) of the 
patients. In a Cox multivariate regression analysis, Lyso- 
Gb3 levels (HR 4.62 (1.55 to 13.81); p=0.006) and the 
pretreatment exposure to Lyso- Gb3 (HR 3.41 (1.11 to 
10.49); p=0.03) (both per SD increase) were significantly 
associated with adverse outcomes. If pretreatment 
Lyso- Gb3 exposure was added to multivariable logistic 
regression models containing age, sex, phenotype and 
enzyme replacement therapy as other covariates with 
the composite outcome as dependent variable, the area 
under the curve for the composite outcome significantly 
improved from 0.72 to 0.86 (p comparison=0.04).
Conclusion Lyso- Gb3 is a significant risk factor 
associated with important clinical events. Whether 
treatment- related amelioration of Lyso- Gb3 levels will be 
associated with improved long- term outcome needs to 
be established in prospective intervention trials.
INTRODUCTION
Fabry disease (FD) is a rare X- linked glycosphin-
golipid storage disease and a result of mutations 
in the α-galactosidase A gene (GLA), which leads 
to reduced activity of the encoded lysosomal exog-
lycohydrolase, α-galactosidase A (α-Gal A) (EC 
3.2.1.22; α-Gal A).1 2 The α-Gal A defect causes the 
progressive accumulation of globotriaosylceramide 
(Gb3) and other related glycosphingolipids in lyso-
somes of patients affected with FD.1
The clinical phenotypes include earlier- onset 
classic, and the attenuated, so- called later- onset 
variants.1 3–5 In the classic phenotype, males with 
little or no residual α-Gal A activity develop marked 
intracellular Gb3- accumulation, with disease signs 
and symptoms, such as acroparesthesias, angiokera-
toma, corneal opacities, hypohidrosis and gastroin-
testinal symptoms, occurring in childhood or early 
adolescence. With advancing age, the progressive 
deposition of glycosphingolipids, particularly in 
vascular endothelial lysosomes, cardiomyocytes 
and kidney podocytes is associated with left ventric-
ular hypertrophy, hypertrophic cardiomyopathy, 
arrhythmias, kidney failure and cerebrovascular 
disease. This results in early demise, typically in 
the fourth or fifth decades of life.6 7 In contrast, 
males with the later- onset phenotype have residual 
α-Gal A activity, no microvascular endothelial 
glycosphingolipid accumulation, and lack the early 
manifestations seen in classic male Fabry patients. 
They present in adulthood with cardiac or, less 
frequently, with kidney disease.3 8–10 Notably, a mild 
biopsy- proven Fabry nephropathy has also been 
reported in the cardiac subtype of the attenuated 
phenotype.11 Female heterozygotes have variable 
expression of FD, ranging from asymptomatic to 
severe, primarily associated with skewed X- chro-
mosomal inactivation.12
Recently, the deacylated derivative of Gb3, 
globotriaosylsphingosine (Lyso- Gb3), has been 
identified as a hallmark of FD.13 Nonetheless, it 
remained highly debated, whether Lyso- Gb3 is 
an independent risk factor for unfavourable clin-
ical events. Arends and colleagues assessed the 
event- free survival time from birth until the first 
clinical event using plasma Lyso- Gb3 at the first 
clinic assessment.5 Thereby, the authors conducted 
a retrospective analysis rather than a prospective 
mortality study because measurements of Lyso- 
Gb3 concentrations had only recently been devel-
oped and established.13 Based on these data for 
a combined cohort of patients with FD, higher 
Lyso- Gb3 concentrations at first clinical visit 
were found to be associated with clinical event 
rate occurring between birth and the time of the 
Lyso- Gb3 measurement. In contrast, analysing 
Lyso- Gb3 concentrations only for classic males 
and females, its levels were not significantly asso-
ciated with previous clinical event rates, although 
classic patients more frequently develop clinical 
events in prospective survival analyses5 and suffer 
from a more severe phenotype. This lack of clarity 
reduces the usefulness of Lyso- Gb3 as a biomarker 
for severity and progression of FD.
Early and accurate risk stratification of patients 
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we have assessed serum Lyso- Gb3 levels as a possible factor asso-
ciated with adverse outcomes in a prospective long- term study 
of a large and well- defined population of genetically confirmed 
Fabry patients. Importantly, all Lyso- Gb3 measurements were 
performed by the same laboratory and using the same analytical 
standards,4 14 and their levels as well as clinical covariates were 
stratified by gender and phenotype.
METHODS
Study population and treatment
This is a retrospective analysis of a prospective cohort; samples 
for the Lyso- Gb3 concentrations were prospectively drawn 
during the routine annual examinations. The entire study period 
was between September 2013 and April 2020. The study was 
conducted in accordance with the principles of the Helsinki 
Declaration. Informed consent for collecting clinical data and 
blood samples was obtained from all patients. All authors have 
read and approved the manuscript.
All patients had a confirmed GLA mutation diagnosis and 
presented for routine annual examinations at our FD centre. 
The cohort was established in 2001 when enzyme replacement 
therapy (ERT) was approved and offered to patients with FD. 
ERT was prescribed at the licensed dose of either 0.2 mg/kg 
body weight of recombinant agalsidase-α (Replagal) or 1 mg/kg 
body weight agalsidase-β (Fabrazyme) and given intravenously 
biweekly. ERT was initiated according to the written local guide-
lines and prescribed as reported previously.15
We measured Lyso- Gb3 in 66 adult patients (males: n=26 
(39%)) at the University Hospital Zurich, Switzerland, between 
September 2013 and December 2016. If patients had more 
than one Lyso- Gb3 measurement, the first result was used for 
the present longitudinal survival analysis. All clinical data were 
extracted from medical records, and the adverse events were 
evaluated during annual examinations as reported previously.15
Phenotyping
All mutations have been classified as coding for the classic or 
later- onset phenotype based on genotype and residual α‐Gal A 
activity in males and are published in the International Fabry 
Disease Genotype/Phenotype Database ( www. dbFGP. org) and in 
previous studies.4 14 Nonsense, frameshift, consensus splice site 
(mutations that can affect the splice- donor and splice- acceptor 
sequences and alter the mature messenger RNA, leading to the 
production of abnormal proteins16) and some missense muta-
tions encode for 0% to 2% residual α‐Gal A activity and lead 
to the classic phenotype in males. Alternative splicing mutations 
and certain other missense mutations encode for >2% of mean 
normal α‐Gal A activity and cause attenuated, the so- called 
later‐onset phenotype in males. The phenotypic assignments 
of the mutations are supported by the clinical manifestations 
in males, the age of symptom onset and by in vitro expression 
assays as reported previously.17 18
Lyso-Gb3 measurement
For serum Lyso- Gb3 levels, blood samples were centrifuged, and 
serum was immediately frozen at −80°C for a later batch anal-
ysis. The samples were measured by high- sensitive electrospray 
ionisation liquid chromatography tandem mass spectrometry 
using an adapted method from Gold. A 7- point serum calibrator 
and an internal standard for Lyso- Gb3 quantification (covering 
the analytic range from 0 to 120 ng/mL; lower limit of quanti-
fication: 0.3 ng/mL) and three- level controls (3, 30 and 100 ng/
mL) for quality control were used (ARCHIMED Life Science 
GmbH, Vienna, Austria; www. archimedlife. com) as previously 
reported.14
Endpoint definition and evaluation
As a primary endpoint, we defined the composite of requiring 
kidney replacement therapy (RRT) (kidney transplantation or 
chronic dialysis), newly diagnosed atrial fibrillation (AF) of any 
type (paroxysmal/persistent), pacemaker and/or implantable 
cardioverter defibrillator (ICD) implantation, cerebrovascular 
events (stroke or transient ischaemic attack (TIA)) diagnosed 
by a neurologist and death, whichever occurred first after the 
baseline serum Lyso- Gb3 measurement. These endpoints, with 
the exception of death, were prospectively defined according 
to Arends et al.5 In contrast to this study, death was added to 
the primary endpoint because of the prospective observational 
period of our study, while this study retrospectively assessed the 
clinical event rates from birth to first visit. It is important to 
note that this previous study did not conduct a mortality study, 
because their patients were included at first visit and retrospec-
tively analysed.5 In our study, the follow- up was censored at the 
date of the first event after the baseline Lyso- Gb3 measurement 
to calculate HRs. The follow- up time for patients without events 
was censored at the 1 April 2020. If the patients died outside of 
the Fabry Centre, the date of death was evaluated by asking the 
responsible general practitioner, the family or the nurse adminis-
tering ERT in the home care setting.
Serum level Lyso- Gb3 at the first measurement (1) and the 
exposure to Lyso- Gb3 before disease- specific treatment (2) 
were employed as primary exposure variables. To calculate the 
cumulative pretreatment exposure to Lyso- Gb3, its serum levels 
measured at baseline of the observational period, all measured 
after September 2013, were multiplied by the age in years of 
the patients at ERT initiation, which was between 2001 and 
2019. Additionally, the exposure to Lyso- Gb3 before diagnosis 
of FD, calculated as product of Lyso- Gb3 levels at baseline and 
age at diagnosis, was employed as exploratory variable. We did 
so under a simplified assumption that the levels of Lyso- Gb3 are 
linear as function of years of age.
Definition of binary covariates
The Lyso- Gb3 measures were classified by their median values, 
stratified by gender and Fabry phenotype (ie, classic vs later- 
onset) to generate a binary covariate with ‘0’ corresponding to 
female gender, later- onset phenotype and Lyso- Gb3 level below 
the median value for each gender and phenotype strata. The 
other binary covariates included median age stratified by gender 
and phenotype at the baseline evaluation, gender, treatment with 
ERT at the time of baseline evaluation and Fabry phenotype.
Statistical analysis
We used descriptive statistics for the baseline characteristics at 
the time of the first Lyso- Gb3 measurement. Categorical vari-
ables were expressed as proportions, continuous variables as 
means with SD or medians with IQRs. Normal distribution was 
assessed by Shapiro- Wilk test. The primary exposure variables 
showed a non- parametric distribution and, therefore, were log- 
transformed for modelling. Comparison of Lyso- Gb3 groups 
according to sex and phenotype was made using one- way anal-
ysis of variance test.
Kaplan- Meier analysis was performed and log- rank test of 
survival distributions equality for patients with baseline serum 















































































































3Nowak A, et al. J Med Genet 2021;0:1–7. doi:10.1136/jmedgenet-2020-107338
Genotype- phenotype correlations
to Lyso- Gb3 before disease- specific treatment (2) above versus 
below median were calculated.
Cox regression analysis was used to examine the mortality 
risk associated with Lyso- Gb3 at the first measurement (1) and 
the exposure to Lyso- Gb3 before disease- specific treatment 
(2). Multivariable models were applied to adjust for potential 
confounders using prior knowledge of variables that have been 
associated with risk in patients with FD in previous studies.5 We 
defined model 1 as a hierarchical adjustment for age; model 2 
for male sex; model 3 for the classic phenotype. These models 
were used for all multivariable Cox regression analyses.
Receiver- operating characteristic (ROC) curves were gener-
ated with multifactor logistic regression models, and the effect 
of adding a specific covariate was evaluated by testing for signif-
icant change in the area under the ROC curve (AUC). The indi-
vidual contributions of two different measures of Lyso- Gb3 
concentrations (baseline Lyso- Gb3 and cumulative Lyso- Gb3 
exposure) as well as a comparison of the contribution of each 
Lyso- Gb3 measure was assessed.
The ROC curves were generated and compared using Stata 
V.16.1 and the roccomp routine. The other statistical analyses 
were performed using the SPSS/PC (V.26.0; SPSS). All statis-
tical tests were two- sided, and p values <0.05 were considered 
significant.
RESULTS
The clinical characteristics at the time of the first Lyso- Gb3 
measurement in all patients according to sex and phenotype 
are shown in online supplemental table 1, the detailed baseline 
demographical and biochemical characteristics in online supple-
mental table 2.
In total, 66 patients (26 males and 40 females) with the median 
age of 44 years were included in the analysis. The highest Lyso- 
Gb3 levels were measured in the classic males, followed by the 
classic heterozygous females. All patients on RRT were male. Of 
50 patients on ERT, 6 were treated with agalsidase-β, 44 with 
agalsidase-α, all at the licensed full dose of each preparation.
Events
No patients were lost to follow- up. During the median follow- up 
time of 68 (40–80) months, the first event occurred in 19 (29%) 
of the patient population. The clinical outcomes are summarised 
in table 1 and are shown in detail in online supplemental table 
3. Five classic patients (males n=4, females n=1) and none later- 
onset patients died during the observational period. Clinical 
events occurred in 18 classic patients (males n=9, females n=9) 
and in one later- onset male (table 1).
Seven patients underwent pacemaker and/or ICD implanta-
tion: three because of a high- degree atrioventricular block, four as 
primary prophylaxis due to high- degree myocardial hypertrophy 
and fibrosis; in three patients, a new- onset of AF occurred; one 
patient received a kidney transplantation, one went on chronic 
dialysis; in one, a stroke occurred; one suffered myocardial 
infarction, five patients died. Overall, 21 events occurred in the 
whole population: one female with pacemaker implantation as 
first event subsequently suffered from two strokes. The distribu-
tion of the incident composite outcome and, separately, death 
during the observational period, according to sex and pheno-
type, is shown in table 2. This table also summarises the late 
disease complications at baseline, when plasma Lyso- Gb3 levels 
were measured.
In males and females, serum levels of Lyso- Gb3 were signifi-
cantly higher in patients who developed events versus patients 
without events (figure 1).
In the Kaplan- Meier analysis, the median of plasma Lyso- Gb3 
levels and of the cumulative pretreatment Lyso- Gb3 exposure 
(figure 2), better than age, sex and phenotype (online supple-
mental figure 1), separated patients with versus without clinical 
events.
In the Cox regression analysis, Lyso- Gb3 levels and the 
pretreatment Lyso- Gb3 exposure were significantly associated 
with the adverse outcomes in the crude model and after the 
adjustment for age in model 1, male sex in model 2 and classic 
phenotype in model 3. This association remained unchanged 
after the exclusion of the six patients with agalsidase-β: for Lyso- 
Gb3 levels HR 2.26 (1.38 to 3.71), p=0.001 in crude model; 
HR 2.50 (1.48 to 4.27), p=0.001 in model 1; HR 4.36 (1.61 to 
11.80), p=0.004 in model 2; HR 5.53 (1.80 to 17.00), p=0.003 
in model 3; for the pretreatment exposure to Lyso- Gb3 HR 
2.93 (1.68 to 5.12), p<0.001 in crude model; HR 2.76 (1.54 to 
4.96), p=0.001 in model 1; HR 3.82 (1.66 to 8.79), p=0.002 
in model 2; HR 3.59 (1.19 to 10.84), p=0.02 in model 3 (all 
per SD increase). In addition, the cumulative exposure to Lyso- 
Gb3 before Fabry diagnosis was significantly associated with the 
adverse outcomes: HR 2.07 (1.52 to 2.82), p<0.001 in crude 
model; HR 2.01 (1.47 to 2.77), p<0.001 in model 1; HR 2.21 
(1.39 to 3.50), p=0.001 in model 2; HR 2.15 (1.31 to 3.53), 
p=0.003 in model 3 (all per SD increase).
The ROC curve indicated a moderate to high association of 
baseline Lyso- Gb3 and the pretreatment Lyso- Gb3 exposure 
with the composite outcome (figure 3).
If pretreatment Lyso- Gb3 exposure was added to the multi-
variable logistic regression model containing age, sex, pheno-
type and ERT as other covariates and the composite outcome as 
dependent variable, the AUC for the composite outcome signifi-
cantly improved from 0.72 to 0.86 (p comparison=0.04).
If baseline Lyso- Gb3 levels were added to the multivariable 
logistic regression model containing the same covariates as 
above, the AUC for the composite outcome improved not signifi-
cantly from 0.72 to 0.77 (p comparison=0.16).













Death, n (%) 4 (20) 1 (2.8) 0 (0) 0 (0)
Composite outcome*, 
n (%)
9 (43) 9 (25) 1 (20) 0 (0)
*Composite of first occurrence of kidney replacement therapy requirement (kidney 
transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or implantable 
cardioverter defibrillator implantation, myocardial infarction, cerebrovascular events (stroke 
or transient ischaemic attack), death.
Table 2 HRs* (and 95% CIs) for occurrence of primary endpoint† 
according to the baseline serum Lyso- Gb3 levels and the pretreatment 
Lyso- Gb3 exposure, both per natural log increase
Baseline Lyso- Gb3 levels Pretreatment exposure to Lyso- Gb3
HR 95% CI P value HR 95% CI P value
Crude 2.12 1.32 to 3.42 0.002 3.02 1.69 to 5.37 <0.001
Model 1 2.45 1.44 to 4.14 0.001 2.88 1.58 to 5.25 0.001
Model 2 3.75 1.44 to 9.73 0.007 3.69 1.60 to 8.51 0.002
Model 3 4.62 1.55 to 13.81 0.006 3.41 1.11 to 10.49 0.03
*Model 1: adjusted for age at Lyso- Gb3 determination; Model 2: additionally, adjusted for male sex; Model 3: 
additionally, adjusted for classic phenotype.
†Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement 
(kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or implantable cardioverter 
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DISCUSSION
In this relatively large well- characterised cohort of genetically 
proven patients with FD, higher baseline levels of Lyso- Gb3 
were associated with a higher risk of complications such as 
death, stroke/TIA, new manifestation of AF, requirement for 
RRT, pacemaker or ICD implantation. More importantly, the 
cumulative exposure to Lyso- Gb3 during the untreated period 
seems to predispose patients with FD to worse clinical outcomes.
These findings correspond to the fact that Lyso- Gb3 reflects 
severity of FD, shown by us4 14 and other groups,19 20 and to 
the fact that Lyso- Gb3 levels in serum correspond to the Gb3 
burden in the vital organs.13 In FD, the correct risk stratification 
based on an understanding of the genotype and phenotype rela-
tionship is an urgent but still unmet clinical need. An increased 
awareness of FD among primary care physicians and specialists 
as well as systematic screening among high- risk populations21 
and newborns22 has been becoming increasingly frequent, 
leading to an increased detection of mutations with unknown 
clinical progression.23 24 A specific biomarker could not only 
fill the diagnostic gap but also improve disease staging and risk 
stratification as well as support the decision whether a patient 
should be started on ERT and or if he should be more closely 
monitored. Of note, patients with FD with low or undetectable 
Lyso- Gb3 levels can still suffer adverse events because of possibly 
having genetic and epigenetic modifiers of their phenotype, 
additional diseases, environmental conditions such as toxins or 
lifestyle modalities. Thus, no biomarker can replace a thorough 
clinical multidisciplinary characterisation, genetic testing and the 
phenotypic descriptions of the family members.
Lyso- Gb3 has been described as a helpful tool for newborn22 
and high- risk group screening,21 25 for diagnosis,26–29 as a 
biomarker for phenotypic assignment,14 a tool reflecting disease 
severity4 and therapeutic monitoring.30–32 As a result of enzy-
matic deficiency, Gb3 accumulation occurs in classic phenotype 
males, already before symptom manifestation.33 34 Lyso- Gb3 
may originate from deacylation of the stored Gb3 or be synthe-
sised by sequential glycosylation of accumulating sphingolipid 
precursors.13 As suggested by our results, the toxic effects of 
Lyso- Gb3 seem to cumulate during the pretreatment period. A 
possible explanation could be that Lyso- Gb3 might not only act 
as a marker of disease severity but also have direct toxic effects 
as a metabolite. Supporting this, Lyso- Gb3 has been demon-
strated to promote Notch1- mediated inflammatory and fibro-
genic response in podocytes, potentially contributing to Fabry 
nephropathy.35 In studies by Sanchez- Niño and colleagues, 
Lyso- Gb3 has been further shown to disrupt the gut microbiota 
homeostasis modulating the biofilm formation of healthy enteric 
bacteria, potentially enhancing the gastrointestinal symptoms of 
patients with FD.36 37 Furthermore, plantar administration of 
Lyso- Gb3 stimulated allodynia in healthy mice; in vitro appli-
cation of Lyso- Gb3 activated Ca2+ uptake of voltage- dependent 
nociceptive neurons, suggesting that this toxic metabolite may 
induce pain through direct actions on sensory afferents.38 More-
over, Aerts and colleagues observed that concentrations of 
Lyso- Gb3, similar to those observed in plasma of symptomatic 
Fabry patients promoted proliferation of smooth muscle cells in 
culture.13
Arends and colleagues observed that ERT initiation at a 
younger age resulted in a more pronounced sustainable decrease 
of Lyso- Gb3, in classic males.31 Noteworthy, plasma Lyso- Gb3 
adequately reflects the cumulative lifetime treatment effect. If 
adding cumulative pretreatment Lyso- Gb3 exposure to the 
logistic regression model containing other important risk factors 
such as age, sex, phenotype and ERT requirement, the AUC for 
the composite outcome significantly improved. Our studies are 
the first to analyse the cumulative pretreatment toxic potential 
of this metabolite. The consequence of this knowledge could be 
that disease- specific treatment aiming at decrease of Lyso- Gb3 
could lower the incidence of the composite endpoint, which 
could be shown by future studies. A possible design of a Lyso- 
Gb3- guided study could be to administer two different doses of 
ERT, which, in the absence of antibodies, would lead to a greater 
decrease of Lyso- Gb330 32 levels and, presumably, to a lower inci-
dence of clinical events, in patients with the higher dose.
The strength of these studies includes a long observational period 
for relevant clinical outcomes in a genetically confirmed one- country 
Figure 1 Baseline serum Lyso- Gb3 levels in patients who developed events versus no events during the observational period. Comparison of Lyso- Gb3 
groups according to sex and phenotype was made using one- way analysis of variance test. The horizontal lines within the boxplots represent medians, the 
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cohort, where patients are treated similarly and exposed to similar 
environmental conditions and complete follow- up data. The latter 
is due to Swiss regulation that the ERT prescription and patient’s 
follow- up remain reserved for the Fabry Centre. Furthermore, an 
under- reporting of clinical events is unlikely in a setting like this, 
where a cohort is personally followed and treated at the same 
specialised centre and by the same treating physician. Disadvantages 
like under- reporting of clinical events and lost to follow- up can 
sometimes limit large registry- based studies.39 In addition, the Lyso- 
Gb3 measurements were conducted at one laboratory with the same 
standards of the technical methods.
These studies are also limited since we analysed the cumulative long- 
term effects of Lyso- Gb3 under the assumption that its levels increase 
with age in a horizontal linear manner. However, Lyso- Gb3, already 
increased in classic Fabry male newborns,13 40 continues rising during 
the presymptomatic phase, representing a metabolic progression to 
the clinical phenotype, and reaches its plateau at the advent of the 
early symptoms.33 Then, it rapidly decreases by approximately 70% 
after 2–3 months of ERT initiation, remaining stable but elevated, 
in patients without antibodies against ERT.30 In contrast, in patients 
with antibodies, Lyso- Gb3 gradually increases again after a decrease, 
following ERT initiation.32 In migalastat- treated patients, Lyso- Gb3 
increases, decreases or remains stable dependent of the degree of 
mutation amenability.41 In our studies, we had to simplify the course 
of Lyso- Gb3 as linear for the calculation of cumulative Lyso- Gb3 
exposure because Lyso- Gb3 had been discovered as a hallmark of 
FD in 200713 and reliable laboratory measurements were available 
even later and were applied in this cohort of adult patients starting 
from 2013.14 Although, Lyso- Gb3 decreases after ERT initiation,30 a 
simplified assumption of linearity seems to be useful to estimate the 
pretreatment cumulative effects to Lyso- Gb3 because (1) ERT was 
initiated relatively late—in the adult age—in this old Fabry cohort, 
and because (2), following ERT, Lyso- Gb3 decreases but remains 
greatly elevated above the normal range.30 Of note, we classified the 
phenotype as published in the International Fabry Disease Genotype/
Phenotype Database ( www. dbFGP. org) for all mutations reported in 
this study. However, it needs to be mentioned that patients with the 
same genotype, sex and similar age can have phenotypic variations 
as previously shown in our4 and other cohorts,42 possibly caused by 
concomitant mutations, epigenetic phenomena and environmental 
conditions. Further limitation is that our results are not entirely in 
line with previous reports that found Lyso- Gb3 not to be associ-
ated with clinical events. Arends and colleagues analysed Lyso- Gb3 
concentrations only for classic males and females, its levels were not 
significantly associated with previous clinical event rates.5 Further 
limitation is that the number of patients is relatively low due to the 
nature of a rare disease. Due to this, a predefined composite outcome 
rather than mortality alone was used to assess risk factors. Therefore, 
further studies are needed to confirm our findings. Finally, for the 
use as a clinical biomarker, standardisation of the technical methods 
and interlaboratory testing is needed in order to compare Lyso- Gb3 
measurements among laboratories.
In conclusion, the major metabolite of FD Lyso- Gb3 appears 
as a potential marker of disease progression and is associated with 
increased risk of mortality and other significant clinical events. The 
cumulative pretreatment exposure to Lyso- Gb3 seems to worsen 
the long- term clinical outcomes, while the disease- specific treatment 
should ameliorate cumulative toxic Lyso- Gb3 effects.
Figure 2 Time to first complication in patients with Fabry disease 
according to serum Lyso- Gb3 levels (A) and the pretreatment exposure to 
Lyso- Gb3 (B), grouped as above andbelow median. The diagram shows the 
results of Kaplan- Meier analysis and log- rank test of survival distribution 
equality.
Figure 3 Accuracy of baseline Lyso- Gb3 levels and the cumulative 
pretreatment exposure to Lyso- Gb3 for the association with the adverse 
outcomes. The diagram represents receiver- operating characteristic curves. 
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